²¡³Ìç×ç¹ ÖØ¸´±¬·¢ ËÄÄêǰ£¬£¬£¬£¬£¬£¬£¬20ËêµÄ֣ijͻȻ·ºÆðÍ·ÔΡ¢ÐÐ×ß²»ÎȵÄÇéÐΣ¬£¬£¬£¬£¬£¬£¬ÓïÑÔÒ²Óеã¿Ú³Ý²»Çå¡£¡£¡£¡£¡£¡£¡£¡£Ëû¸Ïæµ½ÍâµØÒ½Ôº¾ÍÕ£¬£¬£¬£¬£¬£¬³Ê¡°ÖÐÊàÉñ¾ÏµÍ³ÍÑËèÇʲ¡±ä¡±£¬£¬£¬£¬£¬£¬£¬×öÁ˹ѿËÂ¡Çø´ø¼ì²éºÍѪÇå+ÄÔ¼¹Òº¿¹MBP¿¹Ìå¡¢¿¹MOG¿¹Ìå¡¢¿¹AQP4¿¹Ìå¡¢¿¹Flotillin-1/2¿¹Ìå¼ì²é£¬£¬£¬£¬£¬£¬£¬Ð§¹û¾ùΪÒõÐÔ£¬£¬£¬£¬£¬£¬£¬¾¼¤Ëع¥»÷¼°Öð½¥¼õÁ¿ºóÖ¢×´»ù±¾»º½â¡£¡£¡£¡£¡£¡£¡£¡£µ«Ò»¸öÔº󣬣¬£¬£¬£¬£¬£¬Ö¢×´ÓÖ¸´·¢ÁË£¬£¬£¬£¬£¬£¬£¬Õâ´ÎµÄÂÄÔÔöÇ¿MRIÌáÐѲ¡Ôî¹æÄ£½ÏǰÔö´ó¡¢Ç¿»¯½ÏǰÏÔ×ÅÔö¶à£¬£¬£¬£¬£¬£¬£¬ÓèÒÔ¼¤ËØ+±ûÇò¹¥»÷£¬£¬£¬£¬£¬£¬£¬Ö¢×´¸ÄÉÆ¡£¡£¡£¡£¡£¡£¡£¡£ 2023Äê8Ô£¬£¬£¬£¬£¬£¬£¬Ö£Ä³Ôٴθ´·¢¾ÍÕ£¬£¬£¬£¬£¬£¬ÂÄÔÔöÇ¿MRIÌáÐÑ×ó²à¶îÒ¶¡¢ÓÒ²àСÄÔ¡¢Çűۡ¢ÇðÄÔ¼°Á½²à´óÄÔ½ÅÒì³£ÐźÅÓ°£¬£¬£¬£¬£¬£¬£¬Ë¼Á¿Ñ×ÐÔÍÑËèÇʲ¡±ä¿ÉÄܴ󣬣¬£¬£¬£¬£¬£¬ÖÎÁÆÉÏÓèÒÔ¼¤Ëع¥»÷ÖÎÁÆ£¬£¬£¬£¬£¬£¬£¬Ö¢×´¸ÄÉÆºó³öÔº¡£¡£¡£¡£¡£¡£¡£¡£ 2023Äê11Ô£¬£¬£¬£¬£¬£¬£¬Ö£Ä³·ºÆðÓÒÊÖÖ¸²»ÎÞа¡¢°éËÄÖ«³é´¤£¬£¬£¬£¬£¬£¬£¬Í·ÂÔöÇ¿MRIÌáÐÑÓÒ²àСÄÔ°ëÇò¡¢ÄÔ¸ÉÇø¡¢¼äÄÔ¡¢ÓÒ²àÇðÄÔÇø¡¢ÓÒ²à¶î²¿¼°×ó²à¶¥²¿Òì³£Ðźţ¬£¬£¬£¬£¬£¬£¬²¡Ôî½ÏǰÔö¶à¡£¡£¡£¡£¡£¡£¡£¡£
²¦ÔƼûÈÕ Ã÷È·Õï¶Ï ±¸Êܼ²²¡À§ÈŵÄ֣ij¾öÒéתÖÁÉϼ¶Ò½Ôº¾ÍÕï¡£¡£¡£¡£¡£¡£¡£¡£Éϼ¶Ò½ÔºÆðÔ´ÒÔ¡°ÖÐÊàÉñ¾ÏµÍ³ÍÑËèÇʼ²²¡¡±ÊÕÖÎÈëÔº¡£¡£¡£¡£¡£¡£¡£¡£ÈëÔººó£¬£¬£¬£¬£¬£¬£¬Ö£Ä³½ÓÊÜÁËͷ´Ź²Õñ¡¢ÄÔµçͼºÍÑü×µ´©´ÌµÈÏà¹Ø¼ì²é¡£¡£¡£¡£¡£¡£¡£¡£ÃâÒß¼ì²éÌáÐÑ£º¹Ñ¿ËÂ¡Çø´ø¼ì²éΪÒõÐÔ£¬£¬£¬£¬£¬£¬£¬ÑªÇåºÍÄÔ¼¹Òº¿¹AQP4¿¹Ìå¡¢¿¹GFAP¿¹Ìå¡¢¿¹MOG¿¹Ì壨F-CBA·¨£©¾ùΪÒõÐÔ¡£¡£¡£¡£¡£¡£¡£¡£ ΪÁ˽øÒ»²½Ã÷È·Õï¶Ï£¬£¬£¬£¬£¬£¬£¬ÁÙ´²Ò½ÉúÑ¡ÔñÁËмì²âÊÖÒÕ¡ª¡ªMOG¿¹Ìå¼ì²â(L-CBA·¨)£¬£¬£¬£¬£¬£¬£¬¼ì²âЧ¹ûΪѪÇå1£º640¡¢ÄÔ¼¹Òº1£º4ÑôÐÔ¡£¡£¡£¡£¡£¡£¡£¡£ÕâÒ»¼ì²éЧ¹û¸øÁÙ´²Õï¶ÏÌṩÁ˸ü¶àÖ§³ÖÖ¤¾Ý¡£¡£¡£¡£¡£¡£¡£¡£
×ۺϸ÷Ïî¼ì²éЧ¹ûºÍÁÙ´²Ö¢×´£¬£¬£¬£¬£¬£¬£¬×îÖÕÕï¶ÏΪÖÐÊàÉñ¾ÏµÍ³ÍÑËèÇʼ²²¡ÖеÄMOG¿¹ÌåÏà¹Ø¼²²¡£¬£¬£¬£¬£¬£¬£¬Ö¢×´ÐÔñ²ð£¬£¬£¬£¬£¬£¬ÓèÒÔ¼¤ËØÖÎÁÆ£¬£¬£¬£¬£¬£¬£¬¸¨ÒÔ²¹¼Ø¡¢²¹¸Æ¡¢»¤Î¸¡¢²¹ÒºµÈ¶ÔÖ¢ÖÎÁÆ¡£¡£¡£¡£¡£¡£¡£¡£×¡Ôº8Ììºó£¬£¬£¬£¬£¬£¬£¬Ö£Ä³ÉúÃüÌåÕ÷ƽÎÈ£¬£¬£¬£¬£¬£¬£¬ÓÒÊÖ²»ÎÞа½ÏǰÏÔןÄÉÆ¡£¡£¡£¡£¡£¡£¡£¡£
MOG¼°MOG¿¹ÌåÏà¹Ø¼²²¡ ËèÇÊÉÙÍ»½ºÖÊϸ°ûÌÇÂѰף¨myelin oligodendrocyte glycoprotein£¬£¬£¬£¬£¬£¬£¬MOG£©ÊÇÒ»ÖÖ±í´ïÓÚÖÐÊàÉñ¾ÏµÍ³ÉÙÍ»½ºÖÊϸ°ûºÍËèÇÊÍâòµÄÌÇÂѰס£¡£¡£¡£¡£¡£¡£¡£ÃâÒßÒì³£ºóÌåÄÚ½¬Ï¸°ûÉøÍ¸MOG¿¹Ìå(MOG-IgG)£¬£¬£¬£¬£¬£¬£¬½ø¶ø¹¥»÷MOG£¬£¬£¬£¬£¬£¬£¬µ¼ÖÂËèÇʵIJ¿·ÖÍÑʧ£¬£¬£¬£¬£¬£¬£¬ÓÕ·¢MOG¿¹ÌåÏà¹Ø¼²²¡(MOG-IgG asociated disorders£¬£¬£¬£¬£¬£¬£¬MOGAD)¡£¡£¡£¡£¡£¡£¡£¡£ MOGAD¿ÉΪµ¥Ïà»ò¸´·¢²¡³Ì£¬£¬£¬£¬£¬£¬£¬ÆäÁÙ´²±íÐͶàÑù£¬£¬£¬£¬£¬£¬£¬ÈÝÒ×·ºÆðÓëÆäËû¼²²¡ÖصþµÄÇéÐΣ¬£¬£¬£¬£¬£¬£¬Ö÷ÒªÖ¢×´°üÀ¨ÊÓÉñ¾Ñ×£¨optic neuritis£¬£¬£¬£¬£¬£¬£¬ON£©¡¢ÄÔĤÄÔÑס¢ÄÔ¸ÉÄÔÑ׺ͼ¹ËèÑ׵ȡ£¡£¡£¡£¡£¡£¡£¡£ÌÇÆ¤Öʼ¤ËØÖÎÁÆMOGADÓÐÓ㬣¬£¬£¬£¬£¬£¬µ«»¼Õß³£·ºÆð¼¤ËØÒÀÀµ¶øÖظ´±¬·¢¡£¡£¡£¡£¡£¡£¡£¡£´ó¶¼MOGAD»¼ÕßÔ¤ºóÓÅÒ죬£¬£¬£¬£¬£¬£¬²¿·ÖÒÅÁô²Ð¼²¡£¡£¡£¡£¡£¡£¡£¡£ÒòÔÝÎÞÌØÕ÷ÐÔµÄÁÙ´²Ö¢×´¿ÉÒÔÖ±½ÓÌáÐÑMOGADÕï¶Ï£¬£¬£¬£¬£¬£¬£¬ÒÔÊÇMOG¿¹Ìå¼ì²âÓÈΪÖ÷Òª£¬£¬£¬£¬£¬£¬£¬¼ì²âÒªÁìºÍʱ»ú¾öÒéÁË׼ȷÐÔ¡£¡£¡£¡£¡£¡£¡£¡£ MOGADÓëÆäËûÌØ·¢ÐÔÑ×ÐÔÍÑËèÇʼ²²¡£¡£¡£¡£¡£¡£¡£¡£¨IIDDs£©ÔÚÁÙ´²ÌåÏÖ·½ÃæµÄ¹ØÏµÊ¾Òâͼ[1]
¼ì²âÊÖÒÕÉú³¤ÖúÁ¦MOGAD¾«×¼ÕïÁÆ ³£ÓõÄMOG-IgG¼ì²âÒªÁìÓÐÀο¿Ï¸°û¼ì²â£¨F-CBA·¨£©ºÍ»îϸ°û¼ì²â£¨L-CBA·¨£©¡£¡£¡£¡£¡£¡£¡£¡£L-CBA·¨ÓëF-CBA·¨µÄ²î±ðÖ®´¦ÔÚÓÚ²»¾ÙÐÐתȾºóÖÆÆ¬£¬£¬£¬£¬£¬£¬£¬Ö±½ÓʹÓûîϸ°û¾ÙÐкóÐø¼ì²â£¬£¬£¬£¬£¬£¬£¬Äܾ¡¿ÉÄܼá³Ö¿¹ÔµÄ×ÔÈ»¹¹Ï󣬣¬£¬£¬£¬£¬£¬ÔÚÒ»¶¨Ë®Æ½ÉÏ×èֹϸ°ûÔÚÀο¿Àú³ÌÖжԿ¹Ô±í뱬·¢µÄÓ°Ïì¡£¡£¡£¡£¡£¡£¡£¡£ÏÖÔÚ£¬£¬£¬£¬£¬£¬£¬L-CBA·¨Êǹú¼Ê¹«ÈϵÄMOG¿¹Ìå¼ì²âµÄ¡°½ð±ê×¼¡±[2]£¬£¬£¬£¬£¬£¬£¬¿ÉÒÔÔÚÒ»¶¨Ë®Æ½ÉÏ×èֹ©ÕïºÍ¼ÙÑôÐԵı¬·¢¡£¡£¡£¡£¡£¡£¡£¡£ 2019Ä꣬£¬£¬£¬£¬£¬£¬ÍâÑóÅ£½ò¡¢Ã·°ÂµÈ¶àÖÐÐÄÑо¿±ÈÕÕÁËÈýÖÖ»ùÓÚϸ°û¼ì²âMOG-IgGµÄÒªÁìѧ²î±ð£¬£¬£¬£¬£¬£¬£¬Ð§¹ûÅú×¢L-CBA·¨½ÏF-CBA·¨£¬£¬£¬£¬£¬£¬£¬ÑôÐÔÕ¹ÍûÖµ£¨PPV£©¸ü¸ß¡¢Ãô¸ÐÐÔ¸ü¸ßÇÒ¸üÇкÏÁÙ´²ÌØÕ÷[3]¡£¡£¡£¡£¡£¡£¡£¡£ ÉÏÊö¶àÖÐÐÄÑо¿±ÈÕÕ±í¸ñ
2023Äê3Ô£¬£¬£¬£¬£¬£¬£¬Lancet Neurol½ÒÏþ¡¶MOGADµÄÕï¶Ï£º¹ú¼ÊMOGADר¼Ò×齨ÒéµÄÕï¶Ï±ê×¼¡·¡£¡£¡£¡£¡£¡£¡£¡£ÎÄÖÐÖ¸³ö£¬£¬£¬£¬£¬£¬£¬Í¨¹ýÓ«ÏÊÃ÷΢¾µ»òÁ÷ʽϸ°ûÊõ¾ÙÐлùÓÚÈ«³¤ÈËMOGµÄ¡°»îϸ°û¼ì²â¡±ÊÇMOG¿¹ÌåµÄÊ×Ñ¡¼ì²âÒªÁ죻£»£»£»£»¾ßÓÐ×î¸ßµÄÌØÒìÐÔ¡£¡£¡£¡£¡£¡£¡£¡£µ±ÎÞ·¨Ê¹ÓÃL-CBA·¨Ê±£¬£¬£¬£¬£¬£¬£¬Ò²¿ÉʹÓÃF-CBA·¨£¬£¬£¬£¬£¬£¬£¬¿ÉÊÇÃô¸ÐÐÔºÍÌØÒìÐÔ¾ùµÍÓÚL-CBA[4] ¡£¡£¡£¡£¡£¡£¡£¡£
2121·Ç·²ÖÐÊàÉñ¾ÏµÍ³Ñ×ÐÔÍÑËèÇʼ²²¡Ïà¹Ø¼ì²â
2121·Ç·²Ò»Ö±ÖÂÁ¦ÓÚÉñ¾ÏµÍ³¼²²¡¼ì²âµÄÊÖÒÕÑо¿¡¢ÏîÄ¿¿ª·¢ÓëÁÙ´²Ó¦Ó㬣¬£¬£¬£¬£¬£¬Ö¼ÔÚΪÁÙ´²ºÍ»¼ÕßÌṩ¸üʵʱ¡¢¸üÓÅÖʵļì²â·þÎñ£¬£¬£¬£¬£¬£¬£¬ÂÊÏÈÔÚÌìÏ¿ªÕ¹MOG¿¹Ìå»îϸ°û¼ì²â·þÎñ£¬£¬£¬£¬£¬£¬£¬ÖúÁ¦ÁÙ´²Ò½Éú¶ÔÖÐÊàÉñ¾ÏµÍ³Ñ×ÐÔÍÑËèÇʼ²²¡µÄ¾«×¼Õï¶Ï¡£¡£¡£¡£¡£¡£¡£¡£

²Î¿¼ÎÄÏ× [1] ÖйúÃâÒßѧ»áÉñ¾ÃâÒß·Ö»á,Çñΰ,ÐìÑã.¿¹ËèÇÊÉÙÍ»½ºÖÊϸ°ûÌÇÂѰ×ÃâÒßÇòÂѰ×G¿¹ÌåÏà¹Ø¼²²¡Õï¶ÏºÍÖÎÁÆÖйúר¼Ò¹²Ê¶[J].ÖйúÉñ¾ÃâÒßѧºÍÉñ¾²¡Ñ§ÔÓÖ¾,2020,27(02):86-95. [2]Yeh EA, Nakashima I. Live-cell based assays are the gold standard for anti-MOG-Ab testing. Neurology. 2019 Mar 12;92(11):501-502. [3]Waters PJ, Komorowski L, Woodhall M, et al. A multicenter comparison of MOG-IgG cell-based assays. Neurology. 2019;92(11):e1250-e1255. [4]Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023;22(3):268-282.